Purdue Pharma's 2017 Lawsuit: A Deep Dive into the Opioid Crisis
The year 2017 marked a significant turning point in the ongoing opioid crisis, with Purdue Pharma, the manufacturer of OxyContin, facing a barrage of lawsuits. This article delves into the details of these lawsuits, their impact, and the broader context of the opioid epidemic.
Understanding Purdue Pharma and OxyContin
Purdue Pharma, a privately-held pharmaceutical company, is owned by the Sackler family. It introduced OxyContin, a powerful, long-acting opioid painkiller, in 1996. Despite its high potential for abuse, Purdue Pharma aggressively marketed OxyContin, leading to a surge in prescriptions and, subsequently, addiction and overdose deaths.
The 2017 Lawsuits: A Tipping Point
In 2017, several states and counties filed lawsuits against Purdue Pharma, alleging that the company had misled doctors and patients about the risks of OxyContin. These lawsuits were part of a growing wave of legal actions against pharmaceutical companies, distributors, and retailers accused of fueling the opioid crisis.
- State of Ohio vs. Purdue Pharma: Filed in May 2017, this lawsuit accused Purdue Pharma of deceptively marketing OxyContin and contributing to the state's opioid crisis.
- City of Chicago vs. Purdue Pharma: Filed in June 2017, this lawsuit alleged that Purdue Pharma's deceptive marketing practices led to an increase in opioid addiction and overdose deaths in Chicago.
Other Notable 2017 Lawsuits
Other notable lawsuits filed in 2017 included those by the states of Missouri, New Mexico, and the counties of Cuyahoga (Ohio) and Lackawanna (Pennsylvania). These lawsuits echoed similar allegations of deceptive marketing and contributing to the opioid crisis.
The Impact of the 2017 Lawsuits
The 2017 lawsuits against Purdue Pharma brought renewed attention to the opioid crisis and the role of pharmaceutical companies in it. They also set a precedent for future legal actions, with many of the allegations and strategies employed in these lawsuits being replicated in subsequent litigation.
| Year | Number of Opioid-Related Lawsuits Filed |
|---|---|
| 2017 | 15 |
| 2018 | 44 |
| 2019 | 111 |
As the table above shows, the number of opioid-related lawsuits filed each year increased significantly after 2017, indicating the growing recognition of the crisis and the need for accountability.
Purdue Pharma's Response and Settlement
In response to the lawsuits, Purdue Pharma maintained that it had acted responsibly and that its marketing practices were appropriate. However, in 2020, the company filed for bankruptcy as part of a settlement agreement with the U.S. Department of Justice and several states. The settlement included a $3.54 billion criminal penalty and required Purdue Pharma to cease operations and be sold.
The Sackler family also reached a settlement with the Justice Department in 2021, agreeing to pay $225 million and relinquish control of Purdue Pharma. However, many of the lawsuits against Purdue Pharma and the Sackler family continue, with plaintiffs alleging that the settlements do not go far enough in holding the company and the family accountable for their role in the opioid crisis.